Overview

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
0
Participant gender:
All
Summary
This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novo Nordisk A/S
Criteria
Inclusion Criteria:

- Spontaneous intracranial haemorrhage (ICH) within 3 hours after first symptom

Exclusion Criteria:

- Patients with secondary ICH

- Pre-existing disability

- Haemophilia